Balance Sheet

Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Apyx Medical (APYX) Gains from Sales and Divestitures (2024 - 2025)

Apyx Medical filings provide 5 years of Gains from Sales and Divestitures readings, the most recent being $1.5 million for Q4 2025.

On a quarterly basis, Gains from Sales and Divestitures rose 37.31% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 37.31% increase, with the full-year FY2025 number at $1.5 million, up 37.31% from a year prior.
Gains from Sales and Divestitures hit $1.5 million in Q4 2025 for Apyx Medical, up from $1.1 million in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $1.5 million in Q4 2025 to a low of $1.1 million in Q4 2024.